Compare
Fossil Group, Inc. vs Tandem Diabetes Care Inc vs Eastman Kodak Co vs Embecta Corp.
| Latest fiscal year | Fossil Group, Inc. FOSL | Tandem Diabetes Care Inc TNDM | Eastman Kodak Co KODK | Embecta Corp. EMBC |
|---|---|---|---|---|
| Year ended | 2026-01-03 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | $1.00B | $1.01B | $1.07B | $1.08B |
| Revenue growth (YoY) | -12.3% | +7.9% | +2.5% | -3.8% |
| Gross margin | 56.1% | 53.8% | 21.7% | 62.6% |
| Operating margin | -1.9% | -18.5% | 0.0% | 22.4% |
| Net margin | -7.7% | -20.2% | -12.0% | 8.8% |
| Net income | -$77.84M | -$204.71M | -$128.00M | $95.40M |
| EPS (Diluted) | -$1.45 | -$3.04 | -$1.78 | $1.62 |
| Operating cash flow | -$57.90M | -$9.72M | $480.00M | $191.70M |
| Free cash flow | -$60.46M | -$29.67M | $446.00M | $182.40M |
| Cash & equivalents | $95.84M | $90.63M | $337.00M | $225.50M |
| Total assets | $689.25M | $881.11M | $1.62B | $1.09B |
| Total liabilities | n/a | $725.94M | $904.00M | n/a |
| Shareholders' equity | $86.78M | $155.17M | $614.00M | -$650.60M |
| Return on year-end equity | -89.7% | -131.9% | -20.8% | n/a |
| Shares outstanding | 58.35M | 68.29M | 97.40M | 58.50M |
Revenue, most recent five fiscal years
| Fiscal year | Fossil Group, Inc. | Tandem Diabetes Care Inc | Eastman Kodak Co | Embecta Corp. |
|---|---|---|---|---|
| Latest | $1.00B Ended 2026-01-03 | $1.01B Ended 2025-12-31 | $1.07B Ended 2025-12-31 | $1.08B Ended 2025-09-30 |
| 1 year earlier | $1.14B Ended 2024-12-28 | $940.20M Ended 2024-12-31 | $1.04B Ended 2024-12-31 | $1.12B Ended 2024-09-30 |
| 2 years earlier | $1.41B Ended 2023-12-30 | $747.72M Ended 2023-12-31 | $1.12B Ended 2023-12-31 | $1.12B Ended 2023-09-30 |
| 3 years earlier | $1.68B Ended 2022-12-31 | $801.22M Ended 2022-12-31 | $1.21B Ended 2022-12-31 | $1.13B Ended 2022-09-30 |
| 4 years earlier | $1.87B Ended 2022-01-01 | $702.80M Ended 2021-12-31 | $1.15B Ended 2021-12-31 | $1.17B Ended 2021-09-30 |